Reason for request
Inclusion on list of products reimbursed by National Insurance (B/28 and B/98) and for use in hospitals (B/98) in addition to EBIXA 10 mg tablets and EBIXA 10 mg/g oral drops, solution.
Clinical Benefit
| Substantial |
Le service médical rendu par cette spécialité est important dans le traitement des patients atteints d'une forme modérée à sévère de la maladie d'Alzheimer.
|
Clinical Added Value
| no clinical added value |
Cette spécialité est un complément de gamme qui n'apporte pas d'amélioration du service médical rendu.
|
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
Gs90ZdnANtAdwzQD
Listen
